Gene therapy pioneer Uniqure NV is moving into the field of complex disease, by purchasing Inocard GmbH, an early stage German start-up focused on congestive heart failure (CHF), in a cash-and-shares deal valued at €3 million (US$4.01 million) up front. The transaction also includes undisclosed milestone payments and downstream royalties.